Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Pharma (IGC) over the last 15 years, with Q3 2025 value amounting to $29000.0.

  • Pharma's Capital Expenditures changed 0.0% to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $82000.0, marking a year-over-year decrease of 4533.33%. This contributed to the annual value of $112000.0 for FY2025, which is 1884.06% down from last year.
  • Pharma's Capital Expenditures amounted to $29000.0 in Q3 2025, which was down 0.0% from $8000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Capital Expenditures registered a high of $582000.0 during Q4 2022, and its lowest value of -$404000.0 during Q3 2022.
  • Moreover, its 5-year median value for Capital Expenditures was $29000.0 (2024), whereas its average is $48526.3.
  • Data for Pharma's Capital Expenditures shows a peak YoY increase of 205555.56% (in 2022) and a maximum YoY decrease of 136250.0% (in 2022) over the last 5 years.
  • Pharma's Capital Expenditures (Quarter) stood at $27000.0 in 2021, then surged by 2055.56% to $582000.0 in 2022, then crashed by 88.32% to $68000.0 in 2023, then plummeted by 60.29% to $27000.0 in 2024, then rose by 7.41% to $29000.0 in 2025.
  • Its Capital Expenditures stands at $29000.0 for Q3 2025, versus $8000.0 for Q2 2025 and $18000.0 for Q1 2025.